Equities research analysts expect Agenus Inc (NASDAQ:AGEN) to announce earnings of ($0.25) per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Agenus’ earnings. The lowest EPS estimate is ($0.26) and the highest is ($0.24). Agenus reported earnings per share of ($0.37) during the same quarter last year, which indicates a positive year-over-year growth rate of 32.4%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, November 6th.
According to Zacks, analysts expect that Agenus will report full year earnings of ($1.31) per share for the current year, with EPS estimates ranging from ($1.33) to ($1.28). For the next financial year, analysts anticipate that the business will report earnings of ($1.46) per share, with EPS estimates ranging from ($1.47) to ($1.44). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover Agenus.
Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.16.
Several research firms have weighed in on AGEN. BidaskClub cut shares of Agenus from a “strong-buy” rating to a “buy” rating in a research report on Monday, June 18th. Zacks Investment Research upgraded shares of Agenus from a “sell” rating to a “hold” rating in a research report on Wednesday, July 11th.
NASDAQ AGEN traded down $0.01 on Friday, hitting $2.13. 799,380 shares of the stock were exchanged, compared to its average volume of 1,506,848. Agenus has a 52-week low of $1.55 and a 52-week high of $6.19. The company has a debt-to-equity ratio of -0.11, a quick ratio of 1.32 and a current ratio of 1.32. The stock has a market cap of $242.42 million, a price-to-earnings ratio of -1.73 and a beta of 1.84.
A number of hedge funds and other institutional investors have recently bought and sold shares of AGEN. Point72 Asset Management L.P. acquired a new stake in shares of Agenus during the 1st quarter valued at $16,342,000. BlackRock Inc. boosted its stake in shares of Agenus by 15.7% during the 2nd quarter. BlackRock Inc. now owns 5,717,966 shares of the biotechnology company’s stock valued at $12,980,000 after buying an additional 776,715 shares during the period. UBS Group AG boosted its stake in shares of Agenus by 1,180.3% during the 1st quarter. UBS Group AG now owns 137,417 shares of the biotechnology company’s stock valued at $647,000 after buying an additional 126,684 shares during the period. RTW Investments LP boosted its stake in shares of Agenus by 0.7% during the 2nd quarter. RTW Investments LP now owns 9,375,451 shares of the biotechnology company’s stock valued at $21,282,000 after buying an additional 61,895 shares during the period. Finally, Jane Street Group LLC acquired a new stake in shares of Agenus during the 2nd quarter valued at $101,000. Hedge funds and other institutional investors own 35.33% of the company’s stock.
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Further Reading: Closed-End Mutual Funds (CEFs)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.